Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodiesSCHROHL, Anne-Sofie; CHRISTIAN PEDERSEN, Hans; STEEN JENSEN, Sussie et al.Histopathology. 2011, Vol 59, Num 5, pp 975-983, issn 0309-0167, 9 p.Article

Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogelKAGEYAMA, Shinichi; KITANO, Shigehisa; OLD, Lloyd J et al.Cancer science. 2008, Vol 99, Num 3, pp 601-607, issn 1347-9032, 7 p.Article

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerLIPTON, Allan; GOODMAN, Laurie; NEWTON, Alicia et al.Breast cancer research and treatment. 2013, Vol 141, Num 1, pp 43-53, issn 0167-6806, 11 p.Article

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast : A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization studyDOWNS-KELLY, Erinn; YODER, Brian J; STOLER, Mark et al.The American journal of surgical pathology. 2005, Vol 29, Num 9, pp 1221-1227, issn 0147-5185, 7 p.Article

Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cellsLIANG, Chia-Hua; SHIU, Li-Yen; CHANG, Li-Ching et al.Molecular nutrition & food research (Print). 2007, Vol 51, Num 8, pp 999-1005, issn 1613-4125, 7 p.Article

Suitable transmembrane domain significantly increase the surface-expression level of FcεRIα in 293T cellsCHUNXIA QIAO; LEIMING GUO; JIAN SUN et al.Journal of biotechnology. 2009, Vol 139, Num 3, pp 195-202, issn 0168-1656, 8 p.Article

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsKNUEFERMANN, Christiane; YANG LU; BOLIN LIU et al.Oncogene (Basingstoke). 2003, Vol 22, Num 21, pp 3205-3212, issn 0950-9232, 8 p.Article

Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomasENSINGER, Christian; PROMMEGGER, Rupert; KENDLER, Dorotha et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2349-2353, issn 0250-7005, 5 p.Article

In situ detection of HER2:HER2 and HER2:HER3 protein― protein interactions demonstrates prognostic significance in early breast cancerSPEARS, Melanie; TAYLOR, Karen J; MUNRO, Alison F et al.Breast cancer research and treatment. 2012, Vol 132, Num 2, pp 463-470, issn 0167-6806, 8 p.Article

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancerBOYRAZ, Baris; SENDUR, Mehmet A. N; AKSOY, Sercan et al.Current medical research and opinion. 2013, Vol 29, Num 4, pp 405-414, issn 0300-7995, 10 p.Article

Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based AssayWEIDONG HUANG; REINHOLZ, Monica; YUPING TAN et al.American journal of clinical pathology. 2010, Vol 134, Num 2, pp 303-311, issn 0002-9173, 9 p.Article

In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissuesAUBELE, M; SPEARS, M; SCHMITT, M et al.British journal of cancer. 2010, Vol 103, Num 5, pp 663-667, issn 0007-0920, 5 p.Article

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancerYANO, Tomonori; DOI, Toshihiko; OHTSU, Atsushi et al.Oncology reports. 2006, Vol 15, Num 1, pp 65-71, issn 1021-335X, 7 p.Article

Trastuzumab: A Picky Partner?MCARTHUR, Heather L; HUDIS, Clifford A.Clinical cancer research (Print). 2009, Vol 15, Num 20, pp 6311-6313, issn 1078-0432, 3 p.Article

Molecular pathogenesis of bilateral breast cancerIMYANITOV, Evgeny N; HANSON, Kaido P.Cancer letters. 2003, Vol 191, Num 1, pp 1-7, issn 0304-3835, 7 p.Article

HER2/NEU-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapyBUCHHOLZ, Thomas A; HUANG, Eugene H; VALERO, Vicente et al.International journal of radiation oncology, biology, physics. 2004, Vol 59, Num 5, pp 1337-1342, issn 0360-3016, 6 p.Article

Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerationsLAMBEIN, Kathleen; PRAET, Marleen; FORSYTH, Ramses et al.Journal of clinical pathology. 2011, Vol 64, Num 3, pp 200-207, issn 0021-9746, 8 p.Article

Current perspective : TrastuzumabHALL, Peter S; CAMERON, David A.European journal of cancer (1990). 2009, Vol 45, Num 1, pp 12-18, issn 0959-8049, 7 p.Article

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerAMIRI-KORDESTANI, Laleh; BLUMENTHAL, Gideon M; RUSSELL, Anne M et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4436-4441, issn 1078-0432, 6 p.Article

Trastuzumab Combined with Docetaxel-Based Regimens in Previously Treated Metastatic Gastric Cancer Patients with HER2 Over-ExpressionDAI, Guang-Hai; YAN SHI; LI CHEN et al.Hepato-gastroenterology. 2012, Vol 59, Num 120, pp 2439-2444, issn 0172-6390, 6 p.Article

Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: A comparative methodological study using the Ventana BenchMark automated staining system and manual testsBANKFALVI, Agnes; BOECKER, Werner; REINER, Angelika et al.International journal of oncology. 2004, Vol 25, Num 4, pp 929-935, issn 1019-6439, 7 p.Article

Analytical validation and interobserver reproducibility of EnzMet GenePro : A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breastDOWNS-KELLY, Erinn; PETTAY, James; HAINFELD, James et al.The American journal of surgical pathology. 2005, Vol 29, Num 11, pp 1505-1511, issn 0147-5185, 7 p.Article

Protein kinase Cα determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplificationMAGNIFICO, Alessandra; ALBANO, Luisa; CAMPANER, Stefano et al.Cancer research (Baltimore). 2007, Vol 67, Num 11, pp 5308-5317, issn 0008-5472, 10 p.Article

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumoursGELARDI, T; DAMIANO, V; ROSA, R et al.British journal of cancer. 2010, Vol 102, Num 3, pp 513-519, issn 0007-0920, 7 p.Article

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabGRELL, Peter; FABIAN, Pavel; KHOYLOU, Marta et al.International journal of oncology. 2012, Vol 41, Num 4, pp 1204-1212, issn 1019-6439, 9 p.Article